Merck & Co. And Gates Foundation Drug Hunters Hopeful Of A TB Breakthrough
Not-For-Profit To Develop Merck’s Compounds
Executive Summary
The Bill & Melinda Gates Foundation has brought together big pharma companies and academic institutes in a non-profit venture to find new drugs to improve tuberculosis treatment. One participant, Merck & Co, talks to Scrip about two promising novel molecules that it discovered for the Foundation’s Medical Research Institute to develop.
You may also be interested in...
Jemperli Results In Endometrial Cancer Help GSK Build ‘Backbone’ In Immunotherapy
Latecomer PD-1/L1 drug Jemperli has achieved impressive Phase III results in first line endometrial cancer, and GSK hopes it can “redefine” care, especially in dMMR patients. Rival Merck, however, has other ideas.
Pharming’s Portfolio Grows As Ultra-Rare Disease Drug Joenja Is Approved
The first ever approval for ultra-rare immunodeficiency disease APDS gives Pharming its second product on the market but patient diagnosis will be a major challenge.
Novartis’s ‘Poster Child’ Zolgensma Shows What Gene Therapy Can Do – And Its Limitations
The clinical development head of Novartis Gene Therapies talks about the progress for SMA patients more than seven years after treatment began, and hopes of boosting outcomes by treating pre-symptomatic patients.